Fluoride and Vaccine Failures

http://bit.ly/K2a9or FMI

I am sure Mary Selecky, the Washington State Department of Health Secretary, has made no effort to keep up with the facts about vaccines, their toxins, their risk to health, and the options that should be made available to parents as she continues to hawk "Get a Shot" in reaction to the whooping couch outbreak among already vaccinated children. You need this, she says, because the shots wear off.

I am sure Mary also is blind to the damage caused by fluoride as it is forced on thousands of Washington State citizens without their permission in the form of toxic and heavy metal laden fertilizer waste provided by Cargill.

No Mary, fluoride does not truly prevent cavities.  Fluoride also causes fluorosis that impacts teeth and your skeleton.  Fluoride based osteoporosis drugs are implicated in jaw necrosis and now even ADA dentists primed to push this poison on patients are screening for it in the new patient health history form.  Gee, do you think they can connect the dots?

Now, just a week or so after I had a nice talk with a grandmother about the risk of the pertussis shot, I got a great and welcome surprise from JAMA. I was explaining to the grandmother that the nurse who told her daughter in law it was safe to get a pertussis shot while pregnant as it will also help protect the baby is grossly misinforming her, and risking not only her health but that of her baby.

The insanity just seems to get worse by the day, and Selecky's department continues to cover up its own fraud and record destruction to avoid exposing their attack on me for blowing the whistle on insurance fraud, medical record fabrication and extreme patient safety issues . The evidence is compelling.  One of the best pieces is their disregard for factual information they have on my 1977 application for license by endorsement. But this is for another story on another day.

I wrote about how vitamin C can be helpful to parents in this whooping cough situation because I care about public health, something I do not see from WA DOH.  That information is here. There is a legal requirement for any health provider to provide you with both sides of the story, something WA DOH has not done for decades, and probably so have other states and health providers.

While we hear about malaria vaccines and drugs failing Bill Gates continues to push this agenda.  We don't hear about the benefits of vitamin A for this or pneumonia.

While we hear now - at last - about the fraud in medical research -

Critics who deplore the commercialization of medical research have raised concerns about scientific fraud and misconduct that are undermining the integrity of the medical-scientific literature, and the practice of "evidence-based medicine"--- which relies on published journal reports. Recent analyses of retractions of published peer-reviewed journal reports provide supportive evidence for those critics.


Now we have the AMA reporting in its very own publication about the problem with immune suppression and fluoride.  And yes, the outcome is vaccine failure.

Looks like you might not need that extra shot after all.

And to be sure, for the Benton County(WA) Health Department head that did not reply to my correspondence to her, she should know that not all the information found on the internet is questionable.  Does she forget that FDA and CDC are on the internet too, just like the WA DOH.

Should we be trusting what they say?

From Natural Health News

Vaccine does not stop pneumonia

FDA licenses high-dose flu vaccine for elderly

I just finished having a conversation with an investigative reporter regarding over-drugging of the elderly in care homes.  This followed on Diane Sawyer's news piece last evening on ABC News.

Then I happened to check a message from Dr. Tenpenny about a vaccine targetted to the elderly containing foru times the amount of the reguar flu vaccine dose.  The premise is alleged to be because the elderly have a less active immune system.

Someday I hope that these people who beleive that if you have a vaccine for every ailment you will health the world will wake up to the fact that the germ theory was completely debunked and we need to have a new paradigm.

By Robert Roos, News Editor


Dec 28, 2009 (CIDRAP News) – The US Food and Drug Administration (FDA) has approved a high-dose seasonal influenza vaccine for elderly people, whose aging immune systems may not respond effectively to flu vaccines intended for younger people.

The vaccine, Fluzone High-Dose, made by Sanofi Pasteur, contains four times as much antigen (active ingredient) as standard seasonal flu vaccines. The FDA and the company announced its approval Dec 23.

The vaccine is intended for people aged 65 years and older and will be available in time for the 2010-11 flu season, Sanofi officials said in a press release. It apparently is the first flu vaccine licensed in the United States specifically for older people.

In a large phase 3 trial conducted during the 2006-07 flu season, the vaccine induced significantly stronger immune responses than standard-dose vaccine did. Nonserious side effects were more common with the high-dose vaccine, but the overall safety profile was similar to that of the standard vaccine, the company said. The study did not assess actual protection from flu.

The FDA used its "accelerated approval pathway" to review the vaccine, the company having filed its application in March, according to Michelle Yeboah, an FDA spokeswoman. As part of that process, Sanofi will be required to conduct further studies to determine whether the vaccine decreases flu in recipients, the agency said.

"As people grow older, their immune systems typically become weaker," said Karen Midthun, MD, acting director of the FDA's Center for Biologics Evaluation and Research, in the FDA announcement. "This is the first vaccine that uses a higher dose to induce a stronger immune response that is intended to better protect the elderly against seasonal influenza."

Researchers estimate that elderly people account for about 90% of the deaths related to seasonal flu each year. In contrast, younger and middle-aged adults bear most of the burden of severe cases and deaths related to the pandemic H1N1 virus.
Each dose of Fluzone High-Dose will contain 180 micrograms (mcg) of antigen—60 mcg for each of the three flu strains normally targeted in seasonal vaccines, the FDA said. Standard seasonal flu vaccines contain 15 mcg for each strain, for a total of 45 mcg.

Sanofi Pasteur has been the largest producer of flu vaccine for the US market in recent years. Ellyn Schindler, a company spokeswoman, declined to say today how many doses of the high-dose vaccine might be made for the next season, commenting that production plans are proprietary and will depend in part on customer reservations.

"We have two influenza vaccine production facilities licensed in the U.S. which should provide adequate capacity to produce this vaccine as well as our other formulations of influenza vaccines for the 2010-2011 season," Schindler said.

Sanofi made 50.5 million seasonal vaccine doses this year and is producing 75.3 million doses of pandemic H1N1 vaccine, she noted.

The phase 3 trial of Fluzone High-Dose involved 3,856 elderly people, about two thirds of whom received that vaccine and a third the standard dose of Fluzone, according to Sanofi. A report of the trial was published in the Journal of Infectious Diseases (JID) in July.

Volunteers who received the high-dose vaccine had significantly stronger immune responses than those who received the standard dose. The response to the two influenza A strains (H3N2 and H1N1) in the vaccine met predefined superiority criteria, while the response to the B strain met noninferiority criteria, according to the JID report.

Injection-site reactions were more common in those who received the high-dose vaccine, but they were mild to moderate, the report said. The FDA said the rates of serious adverse events were comparable for the two vaccines.

In an editorial that accompanied the JID report, vaccine experts Gregory A. Poland of the Mayo Clinic and Mark J. Mulligan of Emory University commented, "Overall, the rate of adverse events in the HD [high-dose] vaccine group was acceptable although somewhat increased, as would be anticipated" for high-dose trivalent influenza vaccine (TIV).
Multiple studies now have yielded "uniform evidence of enhanced immunogenicity, acceptable reactogenicity, safety, and some evidence of efficacy for HD TIV influenza vaccines," Poland and Mulligan wrote.

It's Old News and You Aren't Getting It

This blog and material found on our original domain, www.leaflady.org, will help you find quite a bit of accurate, scientific information about viruses, cold and flu.

We aren't offering sensationalistic rants as seems to be the driving factor on some other sites. We offer facts and we try to provide information that will help you face health concerns in a more informed and educated approach. We also hope to encourage your enquiring mind so you will seek other corroboration.

Another medical colleague has provided some sound analysis on the current state of flu and vaccines. This doesn't surprise us because the track record for this vaccine, Tamiflu, has been abysmal if you have been tracking the data since the product got the FDA stamp to pass go in exchange for money.

Tamiflu really has been a failure for health but perhaps not for money.

However, since you most likely won't see these latest reports, we'll put them here for your edification.

And remember, the best prevention for flu is good health and sound nutritional status. If you get on this tract, you'll be amazed at the difference, and you'll save a bundle of money over the long term of a healthy life.

Commentary by Dr. Henry Niman www.recombinomics.com

H1N1 Tamiflu Resistance Reporting Delays in North America
November 23, 2008

Based on the level of oseltamivir resistance observed in only one influenza subtype, H1N1, and the persisting high levels of resistance to the adamantanes in H3N2 viruses, CDC continues to recommend the use of oseltamivir and zanamivir for the treatment or prevention of influenza in the United States. Use of amantadine or rimantadine is not recommended.

The above comments from the latest influenza weekly report from the CDC comments on the levels of anti-viral resistance “observed”. However, reports from Europe and North America suggest that virtually all influenza A in the United States this season will be resistant to at least one anti-viral. The resistance rate for H3N2 for amantadines remains at or near 100%. Although test results for this season has been very limited, all H3N2 tested thus far has been resistant to amantadines. Similarly, last season the rate of resistance for the H1N1 sub-clade 2C (Hong Kong) was also 100%. Last season there were two H1N1 sub-clades in circulation in the US, and the rate of Tamiflu resistance for clade 2B (Brisbane/59) was around 10%. However, the level rose to 100% in several countries in the southern hemisphere in the 2008 season, and initial reports from Europe and North America (England, 12/13; Scotland, 2/2; Norway, 1/1; Canada, 1/1; United States, 1/1) suggest the level for clade 2B will be at or near 100% this season.

The numbers “observed” in the United States is low, because the reported number tested is low. In the latest report, the United States has reported 62 H1N1 isolates, but none have been tested for both oseltamivir and amantadine resistance. One isolate collected in September, prior to the official start of this flu season was amantadine resistance, strongly suggesting was clade 2C. One of two isolates tested for Tamiflu resistance this season had H274Y, and it is likely that the other will be amantadine resistant (but test results have not been released) and clade 2C.

Since the level of Tamiflu resistance is expected to be near 100%, it is somewhat surprising that more test results have not been released. The UK has issued an initial report on the 12/13 with H274Y in southwestern England, and has noted that two resistant isolates were also identified in Scotland, indicating the Tamiflu resistance is widespread.

Canada announced the resistance in its first influenza A isolate, but that was over a month ago, and Canada has also not released addition data. Thus, even though the Tamiflu resistance levels of clade 2B are expected to be at or near 100%, each country has only released test results on one clade 2B isolate, and both were resistant, consistent with frequencies reported in Europe this season.

Since most clinicians in North America are unaware of the expectation that the vast majority of Brisbane/59 H1N1 will be Tamiflu resistant, prompt release of test results would be useful.